Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Proteomic profile of faricimab-associated occlusive retinal vasculitis

Eye volume 40, pages 293–296 (2026) Cite this article

Subjects

Faricimab (Vabysmo®; Genentech) is a humanised monoclonal antibody that inhibits both VEGF-A and Ang-2 [1]. It is approved by the U.S. FDA for intravitreal injection (6 mg/0.05 mL) in the treatment of neovascular age-related macular degeneration (nAMD). We previously reported a patient who developed bilateral granulomatous anterior and intermediate uveitis, haemorrhagic occlusive retinal vasculitis, and ocular hypertension after receiving bilateral faricimab injections from two different lots, five days apart (in press). Here, we present the proteomic findings using data-independent acquisition (DIA) analysis, and longer-term outcomes of this patient after 12 months of follow-up.

An 80-year-old woman with bilateral nAMD, presented with acute bilateral blurred vision and ocular pain after receiving intravitreal faricimab injections in both eyes five days apart (left eye first, then right). She had previously been treated with intravitreal aflibercept since 2019 but was switched to monthly faricimab injection four months prior due to suboptimal response. Clinical course has been described in our previous report and is summarised here for completeness.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Fundus and angiographic findings at 12 months.
The alternative text for this image may have been generated using AI.
Fig. 2: Functional enrichment of top differentially abundant proteins.
The alternative text for this image may have been generated using AI.

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM. Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells. 2020;9:1869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Witkin AJ, Hahn P, Murray TG, Arevalo JF, Blinder KJ, Choudhry N, et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J Vitreoretina Dis. 2020;4:269–79.

    Article  Google Scholar 

  3. Iyer PG, Peden MC, Suñer IJ, Patel N, Dubovy SR, Albini TA. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am J Ophthalmol Case Rep. 2020;20:100989.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kondapalli SSA. Retinal vasculitis after administration of brolucizumab resulting in severe loss of visual acuity. JAMA Ophthalmol. 2020;138:1103–4.

    Article  PubMed  Google Scholar 

  5. Haug SJ, Hien DL, Uludag G, Ngoc TTT, Lajevardi S, Halim MS, et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep. 2020;18:100680.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Jain A, Chea S, Matsumiya W, Halim MS, Yaşar Ç, Kuang G, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.

    Article  CAS  PubMed  Google Scholar 

  8. Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study–6 month results. Eye. 2023;37:3574–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126:1155–70.

    Article  PubMed  Google Scholar 

  10. Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399:741–55.

    Article  CAS  PubMed  Google Scholar 

  11. Li Y, Chong R, Fung AT. Association of occlusive retinal vasculitis with intravitreal faricimab. JAMA Ophthalmol. 2024;142:489–91.

    Article  PubMed  Google Scholar 

  12. Cozzi M, Ziegler A, Fasler K, Muth DR, Blaser F, Zweifel SA. Sterile intraocular inflammation associated with faricimab. JAMA Ophthalmol. 2024;142:1028–36.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Witkin AJ, Jaffe GJ, Srivastava SK, Davis JL, Kim JE. Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee. J Vitreoretin Dis. 2024;8:9–20.

    Article  PubMed  Google Scholar 

  14. Agarwal A, Rübsam A, Zur Bonsen L, Pichi F, Neri P, Pleyer U. A Comprehensive update on retinal vasculitis: etiologies, manifestations and treatments. J Clin Med. 2022;11:2525.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Caspi RR, Silver PB, Luger D, Tang J, Cortes LM, Pennesi G, et al. Mouse models of experimental autoimmune uveitis. Ophthalmic Res. 2008;40:169–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Barbour M, Allan D, Xu H, Pei C, Chen M, Niedbala W, et al. IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol. 2014;44:3320–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Read RW, Szalai AJ, Vogt SD, McGwin G, Barnum SR. Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. Exp Eye Res. 2006;82:389–94.

    Article  CAS  PubMed  Google Scholar 

  18. Gupta RC, O’Duffy JD, McDuffie FC, Meurer M, Jordon RE. Circulating immune complexes in active Behçet’s disease. Clin Exp Immunol. 1978;34:213–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Abu El-Asrar AM, Van Damme J, Struyf S, Opdenakker G. New perspectives on the immunopathogenesis and treatment of uveitis associated with Vogt-Koyanagi-Harada disease. Front Med. 2021;8:705796.

    Article  Google Scholar 

  20. Chan CC, Nussenblatt RB, Fujikawa LS, Palestine AG, Stevens G Jr., Parver LM, et al. Sympathetic ophthalmia. Immunopathol Find Ophthalmol. 1986;93:690–5.

    CAS  Google Scholar 

  21. Karle AC, Wrobel MB, Koepke S, Gutknecht M, Gottlieb S, Christen B, et al. Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events. Sci Transl Med. 2023;15:eabq5241.

    Article  CAS  PubMed  Google Scholar 

  22. Kearns JD, Wassmann P, Olgac U, Fichter M, Christen B, Rubic-Schneider T, et al. A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab. Sci Transl Med. 2023;15:eabq5068.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The DIA LC-MS/MS work was supported by the Vincent Coates Foundation Mass Spectrometry Laboratory, Stanford University Mass Spectrometry (RRID:SCR_017801) utilising the Bruker timsTOF Ultra & nanoElute 2 system (RRID: SCR_025639) purchased with generous support from Stanford C-ShaRP. This work was supported in part by NIH P30 CA124435 utilising the Stanford Cancer Institute Proteomics/Mass Spectrometry Shared Resource.

Funding

The Byers Eye Institute is supported by funding from the National Eye Institute (NEI P30-EY026877) and Research to Prevent Blindness, Inc.

Author information

Authors and Affiliations

  1. Spencer Center for Vision Research, Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA

    Jia-Horung Hung, Ishaan Iyer, Nathan Shows, Negin Yavari, Ankur Sudhir Gupta, Dalia El Feky, Ngoc Trong Tuong Than, Amir Akhavanrezayat, Azadeh Mobasserian, Osama Elaraby, Christopher Or & Quan Dong Nguyen

  2. National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, Singapore

    Zheng Xian Thng

  3. Departments of Ophthalmology and Pathology, Stanford University, Stanford, CA, USA

    Andreas Mitsios & Jonathan Lin

  4. Stanford University Mass Spectrometry, Stanford University, Stanford, CA, USA

    Casey A. Powers, Ryan Leib, Fang Liu & Juan Pablo Galindo Lazo

  5. California Retina Consultants, Los Angeles, CA, USA

    Ankur Sudhir Gupta

  6. Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt

    Dalia El Feky

  7. San Luis Obispo Eye Associates, San Luis Obispo, CA, USA

    Daniel R. Agarwal

  8. VA Palo Alto Healthcare System, Palo Alto, CA, USA

    Jonathan Lin

Authors
  1. Jia-Horung Hung
    View author publications

    Search author on:PubMed Google Scholar

  2. Ishaan Iyer
    View author publications

    Search author on:PubMed Google Scholar

  3. Zheng Xian Thng
    View author publications

    Search author on:PubMed Google Scholar

  4. Nathan Shows
    View author publications

    Search author on:PubMed Google Scholar

  5. Negin Yavari
    View author publications

    Search author on:PubMed Google Scholar

  6. Andreas Mitsios
    View author publications

    Search author on:PubMed Google Scholar

  7. Casey A. Powers
    View author publications

    Search author on:PubMed Google Scholar

  8. Ryan Leib
    View author publications

    Search author on:PubMed Google Scholar

  9. Fang Liu
    View author publications

    Search author on:PubMed Google Scholar

  10. Juan Pablo Galindo Lazo
    View author publications

    Search author on:PubMed Google Scholar

  11. Ankur Sudhir Gupta
    View author publications

    Search author on:PubMed Google Scholar

  12. Dalia El Feky
    View author publications

    Search author on:PubMed Google Scholar

  13. Ngoc Trong Tuong Than
    View author publications

    Search author on:PubMed Google Scholar

  14. Daniel R. Agarwal
    View author publications

    Search author on:PubMed Google Scholar

  15. Amir Akhavanrezayat
    View author publications

    Search author on:PubMed Google Scholar

  16. Azadeh Mobasserian
    View author publications

    Search author on:PubMed Google Scholar

  17. Osama Elaraby
    View author publications

    Search author on:PubMed Google Scholar

  18. Christopher Or
    View author publications

    Search author on:PubMed Google Scholar

  19. Jonathan Lin
    View author publications

    Search author on:PubMed Google Scholar

  20. Quan Dong Nguyen
    View author publications

    Search author on:PubMed Google Scholar

Contributions

JHH: conceptualisation, data analysis, writing: original draft; QDN, JL: supervision; NY, AM, CAP, JPL: investigation; all authors: review and editing.

Corresponding author

Correspondence to Quan Dong Nguyen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hung, JH., Iyer, I., Thng, Z.X. et al. Proteomic profile of faricimab-associated occlusive retinal vasculitis. Eye 40, 293–296 (2026). https://doi.org/10.1038/s41433-025-04175-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41433-025-04175-5

Search

Advanced search

Quick links